Q1 2024 Bioatla Inc Earnings Call Transcript
Key Points
- BioAtla Inc (BCAB) reported encouraging data readouts for CAB-ROR2 ADC in treatment-refractory head and neck cancer patients, with a 38% response rate and an 86% disease control rate.
- The company's CAB-CTLA-4 IO antibody showed promising safety results, allowing dose escalation to 700 mg and planning for a 1 gram dose, indicating potential for maximum activity in tumor environments.
- BioAtla Inc (BCAB) completed dosing in the first portion of a potentially registrational trial in undifferentiated pleomorphic sarcoma and plans to evaluate targeting prostate cancer patients.
- Financially, BioAtla Inc (BCAB) reported a decrease in R&D expenses due to the completion of certain preclinical developments and prioritization of clinical programs.
- BioAtla Inc (BCAB) has sufficient cash and cash equivalents to fund operations into the second half of 2025, providing stability for ongoing and planned clinical trials.
- The CAB-ROR2 ADC did not meet the internal efficacy bar for melanoma, leading to a decision not to explore more intensive regimens at this time.
- One patient discontinued treatment due to a treatment-related adverse event of peripheral neuropathy during the safety data cut in March.
- Despite the decrease in R&D expenses, the company reported a net loss of $23.2 million for the quarter ended March 31, 2024.
- Net cash used in operating activities increased in the first quarter of 2024 compared to the same period in 2023, indicating higher cash burn rates.
- The company faces the challenge of needing further follow-up to estimate the duration of response for its CAB-ROR2 ADC in head and neck cancer, which is critical for assessing long-term efficacy.
Yes, greetings, and welcome to the Bayou Atlas First Quarter 2024 earnings call. And at this time, all participants are in a listen only mode. A brief question and answer session will follow the formal presentation. If anyone should require operator assistance during the conference, please press star zero on your telephone keypad. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Bruce, Michael with LifeSci Advisors.
Thank you, Bruce, you may begin.
Thank you, operator, and good afternoon, everyone. And with me today on the phone from bio Atlas are Dr. Jay Short, Chairman, CEO, and Co-Founder, Dr. Eric receivers, Chief Medical Officer, Sherry Lightech, Chief Commercial Officer, and Richard Waldron, Chief Financial Officer.
Following today's call, the team will participate in a short Q&A. Earlier this afternoon, BioAmber released financial results and a business update for the first quarter ended March 31st, 2024. A copy of that press release and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
